Results for

This resolution recognizes the importance of the alliance and friendship between the United States and Germany and the strong ties between the populations and governments, including cooperation under theWunderbar Together-Germany and the U.S.initiative.

This resolution recognizes the 30th anniversary of the fall of the Berlin Wall as the start of German reunification and democratic change in much of the rest of the world. It values the efforts of German and European citizens to reinvigorate the united Germany and recognizes Germany for its steadfast alliance and friendship with the United States.

This resolution recognizes the 30th anniversary of the fall of the Berlin Wall as the start of German reunification and democratic change in much of the rest of the world. It values the efforts of German and European citizens to reinvigorate the united Germany and recognizes Germany for its steadfast alliance and friendship with the United States.

This resolution supports the designation of Oxi Day in commemoration of Greece's refusal to submit to the Axis Powers during World War II and notes that this resistance likely led to the ultimate defeat of Nazi Germany. (Greece's Prime Minister at the time, Ioannis Metaxas, had responded to Italy's demand for surrender with the single wordOxi!orNo!)

This resolution supports the designation of Oxi Day in commemoration of Greece's refusal to submit to the Axis Powers during World War II and notes that this resistance likely led to the ultimate defeat of Nazi Germany. (Greece's Prime Minister at the time, Ioannis Metaxas, had responded to Italy's demand for surrender with the single wordOxi!orNo!)

This resolution expresses remembrance for the genocide of Roma by Nazi Germany and its Axis partners and commemorates the 75th anniversary of the destruction of the "Gypsy Family Camp" where Romani people were interned at Auschwitz. The resolution commends the U.S. Holocaust Memorial Museum for its role in promoting the remembrance of the Holocaust and education about the genocide of Roma. The resolution also expresses support for International Roma Day as an opportunity to honor the culture, history, and heritage of the Romani people in the United States.

This resolution expresses remembrance for the genocide of Roma by Nazi Germany and its Axis partners and commemorates the 75th anniversary of the destruction of the "Gypsy Family Camp" where Romani people were interned at Auschwitz. The resolution commends the U.S. Holocaust Memorial Museum for its role in promoting the remembrance of the Holocaust and education about the genocide of Roma. The resolution also expresses support for International Roma Day as an opportunity to honor the culture, history, and heritage of the Romani people in the United States.

Maintaining United States National Security Interests in Europe Act This bill requires the President to take certain actions before reducing the overall presence of the Armed Forces in Europe, such as by withdrawing Armed Forces or Department of Defense personnel or closing a U.S. military base in Europe. The bill also contains other related provisions. Generally, no later than 180 days before taking an action to reduce the U.S. presence in Europe, the President shall report to Congress (1) a justification for the action, (2) the scope and description of the reduction, (3) an explanation of the action's national security benefit, and (4) a plan to offset the reduction in conventional deterrence against Russian aggression stemming from the action. This requirement shall not apply if (1) a country hosting the U.S. forces requests the reduction in writing, or (2) Congress passes a joint resolution or act expressly authorizing the reduction. The President shall report to Congress a detailed account of the decisionmaking process behind the decision to withdraw Armed Forces members from Germany that was announced on June 15, 2020.

Maintaining United States National Security Interests in Europe Act This bill requires the President to take certain actions before reducing the overall presence of the Armed Forces in Europe, such as by withdrawing Armed Forces or Department of Defense personnel or closing a U.S. military base in Europe. The bill also contains other related provisions. Generally, no later than 180 days before taking an action to reduce the U.S. presence in Europe, the President shall report to Congress (1) a justification for the action, (2) the scope and description of the reduction, (3) an explanation of the action's national security benefit, and (4) a plan to offset the reduction in conventional deterrence against Russian aggression stemming from the action. This requirement shall not apply if (1) a country hosting the U.S. forces requests the reduction in writing, or (2) Congress passes a joint resolution or act expressly authorizing the reduction. The President shall report to Congress a detailed account of the decisionmaking process behind the decision to withdraw Armed Forces members from Germany that was announced on June 15, 2020.

Protecting Europe's Energy Security Act of 2019 This bill directs the President to impose visa- and asset-blocking sanctions on any foreign person that knowingly provides pipe-laying vessels for constructing a Russian-origin energy export pipeline that makes landfall in Germany or Turkey. The President may waive the sanctions as to specific persons if it is in the U.S. national interest to do so and if the President notifies Congress of the decision.

Transparent Drug Pricing Act of 2019 This bill establishes several requirements relating to the prices of prescription drugs. For example, state Medicaid drug-use review programs must require pharmacists to disclose an individual's out-of-pocket cost for a prescription drug, and the price without health insurance, at the point-of-sale. Additionally, health insurers must publish the co-payment amount for each covered prescription drug prior to the annual open-enrollment period. The bill also temporarily prohibits the retail list price of drugs and biologics from exceeding the lowest retail list price among Canada, France, the United Kingdom, Japan, or Germany.

Life-Sustaining Prescription Drug Price Relief Act of 2019 This bill establishes a series of oversight and disclosure requirements relating to the prices of life-sustaining prescription drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all life-sustaining drugs for excessive pricing; HHS must also review prices upon petition. HHS must create a public database with its determinations for each drug and report its overall findings and related activities. Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds 110% of the average price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including cost, revenue, and the size of the affected patient population. The bill also requires drug manufacturers, subject to civil penalties, to (1) report specified financial information for life-sustaining drugs, including research and advertising expenditures; and (2) negotiate the prices of excessively priced life-sustaining drugs under the Medicare prescription drug benefit with HHS.

Prescription Drug Price Relief Act of 2019 This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug. Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including cost, revenue, and the size of the affected patient population. The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.

Prescription Drug Price Relief Act of 2019 This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug. Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including cost, revenue, and the size of the affected patient population. The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.

This resolution recognizes the 81st anniversary of Kristallnacht and honors Jewish victims of the Holocaust. The resolution expresses support for increased awareness of the Holocaust and the eradication of Anti-Semitism internationally.